Expanding opportunities through pharma & biotech partnerships
We are developing unique and differentiated cellular therapies based on regulatory T cells (Treg).
TxCell is the only company globally to be focusing exclusively on antigen-specific Tregs to fight autoimmunity and inflammation. We aim at being the first company in the world to put a CAR-Treg candidate in clinical development, by 2018.
We also aim at fully leveraging our technology and develop an array of CAR‑Tregs as broad as possible.
To achieve this goal, we are actively seeking to partner with world-leading industry players eager to revolutionize medicine.
TxCell brings over 15 years of pioneering work in the science of Tregs, as well as key in-house expertise for all major CAR-Treg development steps.
Our technology platform is versatile, multifaceted and fueled with various Treg populations and mechanisms of action (immune suppression and cytotoxicity). It has the potential to address autoimmune diseases (both T‑cell and B‑cell mediated) in an unprecedently targeted way.